MX366923B - Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento. - Google Patents
Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento.Info
- Publication number
- MX366923B MX366923B MX2016000274A MX2016000274A MX366923B MX 366923 B MX366923 B MX 366923B MX 2016000274 A MX2016000274 A MX 2016000274A MX 2016000274 A MX2016000274 A MX 2016000274A MX 366923 B MX366923 B MX 366923B
- Authority
- MX
- Mexico
- Prior art keywords
- binding
- cross
- antibody
- dual variable
- binding proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a proteínas de unión de tipo anticuerpo que comprenden cuatro cadenas polipeptídicas que forman cuatro sitios de unión al antígeno, en donde cada par de polipéptidos que forman una proteína de unión de tipo anticuerpo posee dominios variables duales que tienen una orientación entrecruzada. La invención también proporciona métodos para elaborar tales proteínas de unión de tipo antígeno.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161468276P | 2011-03-28 | 2011-03-28 | |
FR1160311 | 2011-11-14 | ||
PCT/US2012/030948 WO2012135345A1 (en) | 2011-03-28 | 2012-03-28 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX366923B true MX366923B (es) | 2019-07-31 |
Family
ID=65657124
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016000274A MX366923B (es) | 2011-03-28 | 2012-03-28 | Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento. |
MX2019009016A MX2019009016A (es) | 2011-03-28 | 2013-09-27 | Proteinas de union de tipo anticuerpo con region variable dual que tiene orientacion de la region de union con entrecruzamiento. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019009016A MX2019009016A (es) | 2011-03-28 | 2013-09-27 | Proteinas de union de tipo anticuerpo con region variable dual que tiene orientacion de la region de union con entrecruzamiento. |
Country Status (11)
Country | Link |
---|---|
KR (1) | KR102240802B1 (es) |
CL (1) | CL2013002763A1 (es) |
ES (1) | ES2859906T3 (es) |
HR (1) | HRP20210240T1 (es) |
HU (1) | HUE053139T2 (es) |
IL (3) | IL249369B (es) |
LT (1) | LT3199547T (es) |
MX (2) | MX366923B (es) |
PH (1) | PH12018501305A1 (es) |
PT (1) | PT3199547T (es) |
RU (1) | RU2019122155A (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5989830A (en) * | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
JP5718637B2 (ja) * | 2007-06-21 | 2015-05-13 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディおよびその使用 |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
-
2012
- 2012-03-28 HU HUE16205057A patent/HUE053139T2/hu unknown
- 2012-03-28 KR KR1020197012135A patent/KR102240802B1/ko active IP Right Grant
- 2012-03-28 ES ES16205057T patent/ES2859906T3/es active Active
- 2012-03-28 MX MX2016000274A patent/MX366923B/es unknown
- 2012-03-28 RU RU2019122155A patent/RU2019122155A/ru unknown
- 2012-03-28 PT PT162050579T patent/PT3199547T/pt unknown
- 2012-03-28 LT LTEP16205057.9T patent/LT3199547T/lt unknown
-
2013
- 2013-09-26 CL CL2013002763A patent/CL2013002763A1/es unknown
- 2013-09-27 MX MX2019009016A patent/MX2019009016A/es unknown
-
2016
- 2016-12-04 IL IL24936916A patent/IL249369B/en active IP Right Grant
-
2018
- 2018-06-19 PH PH12018501305A patent/PH12018501305A1/en unknown
-
2020
- 2020-05-24 IL IL274876A patent/IL274876A/en unknown
- 2020-05-24 IL IL274870A patent/IL274870B2/en unknown
-
2021
- 2021-02-11 HR HRP20210240TT patent/HRP20210240T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PT3199547T (pt) | 2021-02-02 |
ES2859906T3 (es) | 2021-10-04 |
IL274870B1 (en) | 2023-01-01 |
KR20190049902A (ko) | 2019-05-09 |
MX2019009016A (es) | 2019-09-10 |
LT3199547T (lt) | 2021-02-25 |
IL274870A (en) | 2020-07-30 |
HRP20210240T1 (hr) | 2021-04-02 |
RU2019122155A (ru) | 2020-03-16 |
IL274870B2 (en) | 2023-05-01 |
IL274876A (en) | 2020-07-30 |
IL249369A0 (en) | 2017-02-28 |
PH12018501305A1 (en) | 2020-01-27 |
HUE053139T2 (hu) | 2021-06-28 |
IL249369B (en) | 2019-11-28 |
KR102240802B1 (ko) | 2021-04-16 |
CL2013002763A1 (es) | 2014-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY164906A (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
PH12018502182A1 (en) | Trispecific and/or trivalent binding proteins | |
MX366223B (es) | Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. | |
MX2022014631A (es) | Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih. | |
PH12017500892A1 (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
EP3461261A4 (en) | PROTEINS BINDING TO THE VARIABLE MONOCATERARY FRAGMENT OF CD3 | |
WO2013033268A3 (en) | Bivalent bromodomain ligands, and methods of using same | |
EP3694871A4 (en) | B-CELL MATURATION ANTIG-BINDING PROTEINS | |
BR112014019579A2 (pt) | Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero | |
SG10201909716RA (en) | Modified j-chain | |
WO2013184939A3 (en) | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide | |
IL290268A (en) | Antigen binding proteins that specifically bind mage-a | |
MX351502B (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
MX358739B (es) | Proteinas de union a amiloide beta. | |
AU2020243430A1 (en) | Antigen binding proteins | |
MX2023004804A (es) | Proteinas de union triespecificas y/o trivalentes. | |
NZ731491A (en) | Cd83 binding proteins and uses thereof | |
GB201919294D0 (en) | Antibodies or binding proteins | |
PH12018501305A1 (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
IL291364A (en) | Antigen binding proteins | |
IL287158A (en) | A multi-specific antigen for binding protein complexes | |
TN2018000345A1 (en) | Trispecific and/or trivalent binding proteins | |
TN2018000137A1 (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
EP3404039A4 (en) | RECOMBINANT PICP PROTEIN AND METHOD FOR PRODUCING SPECIALLY BINDING ANTIBODIES THEREOF | |
TH159427A (th) | โปรตีนยึดเกาะคล้ายแอนติบอดีบริเวณแปรผันคู่ที่มีทิศทางของบริเวณยึดเกาะแบบ ข้ามไขว้ |